Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors
Cell · 2024-09 · 187 (18) · 4905-4925.e24
DOI: 10.1016/j.cell.2024.06.013 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cell, 2024-09. Verfasst von Yikai Luo und 47 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Obstetrics and Gynecology, Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazh…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, T-Lymphocytes, Regulatory, Neoadjuvant Therapy. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Obstetrics and Gynecology, Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Departm…
- National Clinical Research Center for Obstetrics and Gynecology, Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Cancer…
- Department of Gynecology & Obstetrics, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China.
- Precision Scientific (Beijing) Co., Ltd., Beijing 100085, China.
- BioMap (Beijing) Intelligence Technology Limited, Beijing 100089, China.
- Department of Gynecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Zitieren
APA
Luo, Y., Xia, Y., Liu, D., Li, X., Li, H., Liu, J., Zhou, D., Dong, Y., Li, X., Qian, Y., Xu, C., Tao, K., Li, G., Pan, W., Zhong, Q., Liu, X., Xu, S., Wang, Z., Liu, R., …, & Gao, Q. (2024). Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell, 187(18), 4905-4925.e24. https://doi.org/10.1016/j.cell.2024.06.013
Vancouver
Luo Y, Xia Y, Liu D, Li X, Li H, Liu J, et al. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell. 2024;187(18):4905-4925.e24. doi:10.1016/j.cell.2024.06.013
BibTeX
@article{Luo2024,
author = {Luo, Yikai and Xia, Yu and Liu, Dan and Li, Xiong and Li, Huayi and Liu, Jiahao and Zhou, Dongchen and Dong, Yu and Li, Xin and Qian, Yiyu and Xu, Cheng and Tao, Kangjia and Li, Guannan and Pan, Wen and Zhong, Qing and Liu, Xingzhe and Xu, Sen and Wang, Zhi and Liu, Ronghua and Zhang, Wei and Shan, Wanying and Fang, Tian and Wang, Siyuan and Peng, Zikun and Jin, Ping and Jin, Ning and Shi, Shennan and Chen, Yuxin and Wang, Mengjie and Jiao, Xiaofei and Luo, Mengshi and Gong, Wenjian and Wang, Ya and Yao, Yue and Zhao, Yi and Huang, Xinlin and Ji, Xuwo and He, Zhaoren and Zhao, Guangnian and Liu, Rong and Wu, Mingfu and Chen, Gang and Hong, Li and COCPO Consortium, COCPO Consortium and Ma, Ding and Fang, Yong and Liang, Han and Gao, Qinglei},
title = {Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors},
journal = {Cell},
year = {2024},
volume = {187},
number = {18},
pages = {4905--4925.e24},
doi = {10.1016/j.cell.2024.06.013}
}
EUVIMED